Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020
Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved..
The French-speaking Respiratory Medicine Society (SPLF) proposes a guide for the management of possible respiratory sequelae in patients who have presented with SARS-CoV-2 pneumonia (COVID-19). The proposals are based on known data from previous epidemics, preliminary published data on post COVID-19 follow-up and on expert opinion. The proposals were developed by a group of experts and then submitted, using the Delphi method, to a panel of 22 pulmonologists. Seventeen proposals were validated ranging from additional examinations after the minimum assessment proposed in the SPLF monitoring guide, to inhaled or systemic corticosteroid therapy and antifibrotic agents. These proposals may evolve over time as knowledge accumulates. This guide emphasizes the importance of multidisciplinary discussion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 38(2021), 1 vom: 05. Jan., Seite 114-121 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Guide de prise en charge des séquelles respiratoires post infection à SARS-CoV-2. Propositions de prise en charge élaborées par la Société de Pneumologie de Langue Française. Version du 10 novembre 2020 |
|---|
| Beteiligte Personen: |
Andrejak, C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.02.2021 Date Revised 16.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2020.11.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318468255 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318468255 | ||
| 003 | DE-627 | ||
| 005 | 20231225165421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2020.11.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318468255 | ||
| 035 | |a (NLM)33280941 | ||
| 035 | |a (PII)S0761-8425(20)30374-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Andrejak, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020 |
| 246 | 3 | 3 | |a Guide de prise en charge des séquelles respiratoires post infection à SARS-CoV-2. Propositions de prise en charge élaborées par la Société de Pneumologie de Langue Française. Version du 10 novembre 2020 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2021 | ||
| 500 | |a Date Revised 16.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a The French-speaking Respiratory Medicine Society (SPLF) proposes a guide for the management of possible respiratory sequelae in patients who have presented with SARS-CoV-2 pneumonia (COVID-19). The proposals are based on known data from previous epidemics, preliminary published data on post COVID-19 follow-up and on expert opinion. The proposals were developed by a group of experts and then submitted, using the Delphi method, to a panel of 22 pulmonologists. Seventeen proposals were validated ranging from additional examinations after the minimum assessment proposed in the SPLF monitoring guide, to inhaled or systemic corticosteroid therapy and antifibrotic agents. These proposals may evolve over time as knowledge accumulates. This guide emphasizes the importance of multidisciplinary discussion | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Fibrose | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a Pneumonie | |
| 650 | 4 | |a Pneumopathie interstitielle diffuse | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sequelae | |
| 650 | 4 | |a Séquelles | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Cottin, V |e verfasserin |4 aut | |
| 700 | 1 | |a Crestani, B |e verfasserin |4 aut | |
| 700 | 1 | |a Debieuvre, D |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Bermejo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Morelot-Panzini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Stach, B |e verfasserin |4 aut | |
| 700 | 1 | |a Uzunhan, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Maitre, B |e verfasserin |4 aut | |
| 700 | 1 | |a Raherison, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 38(2021), 1 vom: 05. Jan., Seite 114-121 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2021 |g number:1 |g day:05 |g month:01 |g pages:114-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2020.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2021 |e 1 |b 05 |c 01 |h 114-121 | ||